Prelude Capital Management, LLC Chimerix Inc Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.91 - $1.26 $37,674 - $52,164	41,400 New	41,400 $43,000
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.35 $31,396 - $44,180	18,800 New	18,800 $34,000
Q2 2022 Aug 15, 2022	BUY	$1.34 - $5.34 $5,711 - $22,759	4,262 Added 2.94%	149,179 $310,000
Q1 2022 May 16, 2022	BUY	$4.58 - $6.8 $201,671 - $299,424	44,033 Added 43.65%	144,917 $664,000
Q4 2021 Feb 14, 2022	BUY	$5.23 - $7.18 $249,931 - $343,117	47,788 Added 90.0%	100,884 $649,000
Q3 2021 Nov 15, 2021	BUY	$5.94 - $8.75 $50,032 - $73,701	8,423 Added 18.85%	53,096 $329,000
Q2 2021 Aug 16, 2021	BUY	$7.54 - $9.79 $336,834 - $437,348	44,673 New	44,673 $357,000
Q1 2021 May 17, 2021	SELL	$4.76 - $11.25 $266,317 - $629,426	-55,949 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.43 - $5.42 $190,259 - $424,364	-78,296 Reduced 58.32%	55,949 $270,000
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.72 $115,947 - $187,532	-50,412 Reduced 27.3%	134,245 $334,000
Q2 2020 Aug 14, 2020	BUY	$1.33 - $3.63 $245,593 - $670,304	184,657 New	184,657 $572,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.